Cytochrome P450 2W1: Identification of new inhibitors, active site ligands, and pharmacophores. [PDF]
J Biol ChemFrydendall EK, Scott EE.
europepmc +1 more source
Development of a high throughput cytochrome P450 ligand-binding assay. [PDF]
J Biol ChemFrydendall EK, Scott EE.
europepmc +1 more source
Distinct effects of psychiatric disorder diagnoses and severe emotional dysregulation on matrix metalloproteinase-9, proinflammatory cytokines, and inhibitory control function in adolescents with attention-deficit hyperactivity disorder or first-episode major affective disorders. [PDF]
Int J NeuropsychopharmacolHsu JW +4 more
europepmc +1 more source
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer. [PDF]
Exp Hematol OncolZhang M, Zhang B.
europepmc +1 more source
Matrix Metalloproteinases and Their Inhibitors in the Pathogenesis of Epithelial Differentiation, Vascular Disease, Endometriosis, and Ocular Fibrotic Pterygium. [PDF]
Int J Mol SciPark JY +5 more
europepmc +1 more source
Localized Affinity-Based Delivery of Prinomastat for Cancer Treatment
ACS Biomaterials Science and Engineering, 2017 Glioblastoma multiforme patients suffer a median survival of 14 months, facilitated by the highly invasive nature of this cancer that allows for it to evade conventional therapy. Prinomastat targets the essential matrix metalloproteinase degradation of the extracellular matrix needed for cancer invasion; however, its clinical potential is impeded by ...
Edgardo Rivera-Delgado +1 more
exaly +4 more sources
Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non–Small-Cell Lung Cancer
Journal of Clinical Oncology, 2005 Purpose Matrix metalloproteinases (MMPs) degrade extracellular proteins and facilitate tumor growth, invasion, metastasis, and angiogenesis. This trial was undertaken to determine the effect of prinomastat, an inhibitor of selected MMPs, on the survival of patients with advanced non–small-cell lung cancer (NSCLC), when given in combination with ...
Joachim von Pawel +2 more
exaly +5 more sources
Investigational New Drugs, 2006 This randomized phase II, parallel-design study evaluated preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with resectable adenocarcinoma of the esophagus that were stage II or greater. The objectives of the trial were to determine pathologic complete response rate (pCR), overall response ...
Jonathan Knisely +2 more
exaly +4 more sources
Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2006 AbstractBACKGROUND: Matrix metalloproteinases (MMPs) play key roles in remodeling of the extracellular matrix during embryogenesis and fetal development. The objective of this study was to determine the effects of prinomastat, a potent selective MMP inhibitor, on fetal growth and development.
Husam S, Younis +3 more
exaly +4 more sources
Current Eye Research, 2002 We studied the effects of intravitreally administered prinomastat on the take rate and growth of uveal melanoma after xenograft implantation in rabbit uveal melanoma model.Uveal melanoma xenograft was implanted to suprachoroidal space in each eye of 24 pigmented rabbits which were immunosuppressed with cyclosporine.
Nissi Varki +2 more
exaly +4 more sources